INT15920

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1988
Last Reported 2010
Negated 9
Speculated 1
Reported most in Abstract
Documents 34
Total Number 36
Disease Relevance 17.36
Pain Relevance 4.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Serpine1) extracellular region (Serpine1)
Anatomy Link Frequency
plasma 6
coronary artery 2
platelet 2
blood 1
coronary sinus 1
Serpine1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
metalloproteinase 13 99.48 Very High Very High Very High
acular 6 99.34 Very High Very High Very High
Angina 42 98.44 Very High Very High Very High
Inflammation 104 98.32 Very High Very High Very High
cytokine 31 94.92 High High
antagonist 4 94.08 High High
Restless leg syndrome 5 92.76 High High
fibrosis 10 84.88 Quite High
Pain 10 79.44 Quite High
ischemia 3 76.72 Quite High
Disease Link Frequency Relevance Heat
Coronary Artery Disease 63 100.00 Very High Very High Very High
Disorder Of Lipid Metabolism 6 100.00 Very High Very High Very High
Metabolic Syndrome 4 98.84 Very High Very High Very High
Atherosclerosis 5 98.56 Very High Very High Very High
Diabetes Mellitus 29 98.50 Very High Very High Very High
Cv General 3 Under Development 41 98.44 Very High Very High Very High
INFLAMMATION 117 98.32 Very High Very High Very High
Disease 26 97.64 Very High Very High Very High
Malignant Neoplastic Disease 2 97.60 Very High Very High Very High
Pathologic Processes 2 95.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The PAI-1 levels were not significantly different in the three groups.
Neg (not) Regulation (different) of PAI-1
1) Confidence 0.42 Published 2006 Journal Pharmacology Section Body Doc Link 17057417 Disease Relevance 0.06 Pain Relevance 0
Besides the effect of the metabolic status on plasma PAI-1 levels, the role of a genetic control has been emphasized, but according to recent results obtained in a family segregation study, its participation seems limited.
Regulation (effect) of PAI-1 in plasma
2) Confidence 0.41 Published 1997 Journal Thromb. Haemost. Section Abstract Doc Link 9198234 Disease Relevance 1.05 Pain Relevance 0.08
In contrast, PAI-1 levels in the RA group remained unchanged over time.
Neg (unchanged) Regulation (unchanged) of PAI-1
3) Confidence 0.41 Published 1993 Journal Anesthesiology Section Body Doc Link 8363067 Disease Relevance 0 Pain Relevance 0
Increased plasma levels of plasminogen activator inhibitor-1 (PAI-1) have been shown to exist in 40 to 60% of patients with stable coronary artery disease and have been suggested to be responsible for the development of coronary thrombotic complications.
Regulation (responsible) of PAI in coronary artery associated with coronary artery disease
4) Confidence 0.40 Published 1990 Journal Thromb. Haemost. Section Abstract Doc Link 2119522 Disease Relevance 0.94 Pain Relevance 0.44
In several in vitro studies, Serpine1 has been shown to regulate, and to be regulated by TGF-?
Regulation (regulate) of Serpine1
5) Confidence 0.40 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2688838 Disease Relevance 0.67 Pain Relevance 0.18
Serpine1 is highly up-regulated at day 3, but decreases after that.
Regulation (regulated) of Serpine1
6) Confidence 0.29 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2688838 Disease Relevance 0.79 Pain Relevance 0.24
Addition of progesterone to estrogen did not reverse effects of the estrogen alone phase of either PAI-1 or tPA values.
Neg (not) Regulation (effects) of PAI-1
7) Confidence 0.25 Published 1996 Journal Am. J. Cardiol. Section Abstract Doc Link 8888658 Disease Relevance 0.15 Pain Relevance 0.05
The present study was conducted to compare the efficacy, safety, cost-effectiveness and effects on plasminogen activator inhibitor-1 (PAI-1) levels of three LMWHs--enoxaparin, nadroparin and dalteparin.
Regulation (effects) of PAI-1
8) Confidence 0.25 Published 2006 Journal Pharmacology Section Abstract Doc Link 17057417 Disease Relevance 0 Pain Relevance 0.10
Similarly, there was no difference in coronary sinus or systemic (aortic) PAI-1 activity among the three groups: the coronary sinus PAI-1 activity was 8.2 +/- 2.0, 7.4 +/- 2.0, and 8.0 +/- 2.5 AIU/ml in the control, unstable angina, and stable angina groups, respectively (NS).
Regulation (control) of PAI-1 in coronary sinus
9) Confidence 0.22 Published 1996 Journal Coron. Artery Dis. Section Body Doc Link 8773432 Disease Relevance 0 Pain Relevance 0
Genes such as gelatinase A (MMP2), cathepsin L, tissue inhibitor metalloproteinases 2 (TIMP2) and 3 (TIMP3), plasminogen activator inhibitor1 (PAI1), tissue type plasminogen activator (tPA), urokinase plasminogen activator (tPA), endothelin 1, calponin, carboxypeptidase D and calponin acidic were down regulated.
Regulation (regulated) of PAI1 associated with metalloproteinase
10) Confidence 0.21 Published 2005 Journal Reprod Biol Endocrinol Section Abstract Doc Link PMC548144 Disease Relevance 0.07 Pain Relevance 0.05
Genes such as gelatinase A (MMP2), cathepsin L, tissue inhibitor metalloproteinases 2 (TIMP2) and 3 (TIMP3), plasminogen activator inhibitor1 (PAI1), tissue type plasminogen activator (tPA), urokinase plasminogen activator (tPA), endothelin 1, calponin, carboxypeptidase D and calponin acidic were down regulated.
Regulation (regulated) of plasminogen activator inhibitor1 associated with metalloproteinase
11) Confidence 0.21 Published 2005 Journal Reprod Biol Endocrinol Section Abstract Doc Link PMC548144 Disease Relevance 0.08 Pain Relevance 0.05
Ketorolac infusion elicited a significant response in PAI-1 activity within 24 h post-operation and this was not seen in the non-ketorolac group in spite of the rising trend by 24 h post-operation which did not achieve statistical significance.
Regulation (response) of PAI-1 associated with acular
12) Confidence 0.21 Published 1995 Journal Thromb. Res. Section Abstract Doc Link 7502276 Disease Relevance 0.18 Pain Relevance 0.40
Among others, the presence of metabolic syndrome and the -675 4G/5G promoter polymorphism are known to be modulators of PAI-1 levels.
Regulation (modulators) of PAI-1 associated with metabolic syndrome
13) Confidence 0.14 Published 2008 Journal Curr. Med. Chem. Section Abstract Doc Link 18473800 Disease Relevance 0.63 Pain Relevance 0.07
Patients with unstable coronary artery disease were randomly treated either with a combination therapy consisting of nitrates and calcium-channel blockers without or with addition of clinical grade heparin administered subcutaneously; in order to evaluate the effect of heparin treatment on the fibrinolytic system, tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) plasma levels were related to the clinical course of the disease.
Regulation (effect) of PAI-1 in plasma associated with coronary artery disease and disease
14) Confidence 0.13 Published 1989 Journal Thromb. Res. Section Abstract Doc Link 2506671 Disease Relevance 0.27 Pain Relevance 0.07
CONCLUSIONS: Although it has been suggested that alterations in local (transmyocardial) t-PA and PAI-1 activities may be of pathophysiologic importance in the genesis of unstable angina, our data show no difference in transmyocardial fibrinolytic activity in patients with unstable angina, stable angina, and noncardiac chest pain.


Regulation (alterations) of PAI-1 in chest
15) Confidence 0.13 Published 1996 Journal Coron. Artery Dis. Section Body Doc Link 8773432 Disease Relevance 0 Pain Relevance 0
PAI levels were unrelated to sex or age in both the patient and the control groups.
Regulation (unrelated) of PAI
16) Confidence 0.13 Published 1988 Journal Klin. Wochenschr. Section Abstract Doc Link 3258044 Disease Relevance 0.42 Pain Relevance 0.26
Although E2 alone did not affect PAI-1 output, MPA and E2+MPA significantly enhanced PAI-1 production (2.5 +/- 0.7 vs 8.2 +/- 2.0 ng/mL per microg protein for E2+MPA [3.3-fold]; P < .01).
Neg (not) Regulation (affect) of PAI-1
17) Confidence 0.13 Published 2007 Journal Am. J. Obstet. Gynecol. Section Body Doc Link 17403427 Disease Relevance 0 Pain Relevance 0
The present study evaluated the concentrations of PAI-1 and several fibrinolytic factors in the plasma and platelets of patients with CAD and the serial changes in patients with acute myocardial infarction (AMI).
Regulation (concentrations) of PAI-1 in platelets associated with coronary artery disease and myocardial infarction
18) Confidence 0.11 Published 2000 Journal Jpn. Circ. J. Section Abstract Doc Link 10952148 Disease Relevance 1.14 Pain Relevance 0.14
Neither drug had an effect on tissue-type plasminogen activator or plasminogen activator inhibitor type 1 (PAI-1).
Regulation (effect) of PAI-1
19) Confidence 0.11 Published 1994 Journal Eur. J. Clin. Pharmacol. Section Abstract Doc Link 7915237 Disease Relevance 0.17 Pain Relevance 0.14
Because only diabetics with coronary artery disease (CAD) showed a decreased fibrinolytic capacity, a second study was performed on the 16 non-diabetic CAD patients to determine whether submaximal workload induces significant changes of tPA and PAI levels.
Spec (whether) Regulation (changes) of PAI in coronary artery associated with coronary artery disease and diabetes mellitus
20) Confidence 0.11 Published 1991 Journal Blood Coagul. Fibrinolysis Section Abstract Doc Link 1772997 Disease Relevance 2.40 Pain Relevance 0.38

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox